西罗莫司在儿科患者中的群体药代动力学研究进展

Research progress on population pharmacokinetics of sirolimus in pediatric diseases

西罗莫司为大环内酯类免疫抑制剂,近年来广泛应用于儿科结节性硬化症、免疫相关疾病及脉管畸形和血管瘤。西罗莫司在患者体内的药动学过程存在较大的个体差异,因此,有必要进行治疗药物监测,并使用群体药代动力学(PPK)方法指导并优化给药方案。目前,由于国内外关于西罗莫司的PPK研究有限,模型尚不成熟,本文重点总结西罗莫司PPK的研究进展,讨论西罗莫司模型优化的改进措施,以利于未来进行西罗莫司在不同疾病中PPK模型的建立及个体化治疗的发展。

Sirolimus is a macrolide immunosuppressant commonly used to treat pediatric patients with tuberous sclerosis,immune-related diseases,vascular anomalies,and vascular tumors in recent years.However,there are significant interindividual differences in the pharmacokinetic processes of sirolimus within patients,which necessitates regular therapeutic drug monitoring.The application of population pharmacokinetic(PPK)methods is crucial in guiding and optimizing dosing regimens.Currently,due to the limited scope of domestic and international studies on sirolimus PPK,the existing models are not fully developed.This article provides a comprehensive summary of the progress in sirolimus PPK research,discussing measures for optimizing sirolimus models.The review aims to facilitate the future establishment of PPK models for sirolimus in various diseases and the development of individualized treatment approaches.